Updated

Researchers report that an experimental drug called CS18 may help overcome cancer's resistance to treatment by disabling multiple survival defenses tumors use against therapy. In lab and animal studies, CS18 strengthened existing cancer therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth. The findings suggest a potential new strategy for combating drug-resistant cancers, though further clinical development is needed.